Breakpoint Therapeutics

Breakpoint Therapeutics is a private biotechnology company based in Hamburg, Germany, founded in 2019 as a spin-off from Evotec SE.

The company specializes in developing targeted cancer therapies that focus on modulating the DNA damage response and related pathways to address therapy-resistant and hard-to-treat cancers. The company is engaged in oncology drug discovery and development, with a preclinical pipeline that includes investigational drug candidates targeting DNA Polymerase Theta and Werner Helicase. Breakpoint Therapeutics aims to create first-in-class and best-in-class therapeutics that can enhance or replace existing treatments, such as PARP inhibitors. Its research is centered on innovative approaches that leverage synthetic lethality to selectively target cancer cells while sparing healthy cells. Breakpoint Therapeutics has secured approximately $33.7 million in funding from various investors, including Medicxi, Taiho Ventures, Evotec, and BVF Partners.